• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Differential response to panitumumab seen in colorectal cancer based on genotypes

bys25qthea
September 12, 2013
in Chronic Disease, Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Addition of panitumumab to the first-line FOLFOX4 regimen prolonged survival in patients without RAS mutations. 

2. Panitumumab was associated with shortened survival in patients with certain RAS mutations. 

Evidence Rating Level: 1 (Excellent)     

Study Rundown: This study demonstrated the genetic heterogeneity of colorectal cancer and the resultant complications in finding the optimal treatment regimen. Adding panitumumab to the established first-line regimen of oxaliplatin, fluorouracil and leucovorin (FOLFOX4) was associated with better survival outcomes in some tumor genotypes and worse outcomes in others. As such, selection of the optimal treatment should take into account the specific genetic markers of the tumor, among other considerations. This conclusion reasonably applies to other types of cancer where high genetic heterogeneity is common. The study is strong with a large sample size and is well-controlled for subgroup differences. Amgen is the study sponsor and the manufacturer for panitumumab.

Click to read the study, published today in NEJM

Click to read an accompanying editorial in NEJM

RELATED REPORTS

Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk

Shortened duration of adjuvant chemotherapy in individuals with stage III colon cancer may be associated with noninferior overall survival

#VisualAbstract: Pembrolizumab linked to longer cancer-free period in advanced MSI-H-dMMR colorectal cancer

Relevant Reading: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

In-Depth [prospective-retrospective analysis]: This study analyzed the survival and progression benefits of adding panitumumab to oxaliplatin, fluorouracil and leucovorin (FOLFOX4) as it related to tumor genotypes.

In patients without RAS mutation, the panitumumab-FOLFOX4 group had better progression-free survival (10.1 vs 7.9 months, P=0.004) as well as better overall-survival (26.0 vs 20.2 months, P=0.04) compared to the FOLFOX4 group. In patients without KRAS mutation in exon 2, the panitumumab-FOLFOX4 group had better progression-free survival compared to the FOLFOX4 group (9.6 vs 8.0 months, P=0.02). Overall survival also favored addition of panitumumab but was not statistically significant (23.9 vs 19.7 months, P=0.07).

In patients without KRAS exon 2 mutation but with other RAS exon mutations, progression-free survival and overall survival were shorter with addition of panitumumab, though this was not statistically significant. Panitumumab-FOLFOX4 group had inferior progression-free survival in patients with KRAS mutations in exon 2 (7.3 vs 8.8 months, P=0.02). As such, the survival benefit of adding panitumumab to the FOLFOX4 regimen was not consistent across tumour genotypes.

By Xiaozhou Liu and Adrienne Cheung 

More from this author: Nivolumab plus ipilimumab shows promise for metastatic melanoma, Prophylactic platelet transfusions prevent bleeding in hematologic cancers, Azithromycin is not associated with increased cardiovascular death in low-risk groups, Health education module reduces parasitic infections, New chemotherapy precludes the need for radiotherapy in primary mediastinal B-cell lymphoma.

 

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: colon cancerpanitumumab
Previous Post

Vitamin D supplementation not associated with reduced diarrheal illness

Next Post

Testosterone and estrogen exert independent effects in the pathogenesis of male hypogonadism

RelatedReports

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Chronic Disease

Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk

March 20, 2023
Racial differences in colorectal cancer survival linked to health at initial diagnosis
2 Minute Medicine

Shortened duration of adjuvant chemotherapy in individuals with stage III colon cancer may be associated with noninferior overall survival

June 2, 2021
#VisualAbstract: Occult Blood in Feces Is Associated With an Increased Risk of Ischemic Stroke and Myocardial Infarction
Chronic Disease

#VisualAbstract: Pembrolizumab linked to longer cancer-free period in advanced MSI-H-dMMR colorectal cancer

January 28, 2021
Radiofrequency ablation of hepatic metastases in colorectal cancer linked with improved survival
Gastroenterology

Addition of bevacizumab to standard therapy improves outcomes in metastatic colorectal cancer

August 31, 2020
Next Post
Testosterone and estrogen exert independent effects in the pathogenesis of male hypogonadism

Testosterone and estrogen exert independent effects in the pathogenesis of male hypogonadism

Industry influences on expert panels contribute to over-diagnosis

Pay for performance has modest effect on hypertension care

CTA as an alternative to angiography for blunt cerebrovascular trauma detection

Asian Americans suffer higher in-patient mortality following sub-arachnoid hemmorhage

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options